InnFocus MicroShunt Versus Trabeculectomy Study

Overview

Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma medications.

Full Title of Study: “A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShunt® Glaucoma Drainage System to Standard Trabeculectomy In Subjects With Primary Open Angle Glaucoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: January 15, 2020

Detailed Description

This clinical trial is a prospective, randomized, controlled, multicenter, study. After informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity. Clinical follow up will be scheduled over the course of the 24 month study, and examinations will be repeated to monitor eye health. At the 1 and 2 year follow up, diurnal (IOP taken in the morning, mid-day, and afternoon in the same day) IOP evaluation will be done. Annual follow up will occur up to 2 years. The primary effectiveness endpoint is 20% or greater reduction in IOP from pre-op medicated IOP at 12 months.

Interventions

  • Procedure: Glaucoma Surgery
    • An initial pocket is created under the conjunctiva and Tenon’s capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a “fornix-based” conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm’s canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure.
  • Device: InnFocus MicroShunt
    • An initial pocket is created under the conjunctiva and Tenon’s capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a “fornix-based” conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure.

Arms, Groups and Cohorts

  • Experimental: InnFocus MicroShunt
    • InnFocus MicroShunt
  • Active Comparator: Trabeculectomy
    • glaucoma surgery to reduce IOP

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With > 20% Decrease in Mean Diurnal Intraocular Pressure
    • Time Frame: 12 months
    • The primary effectiveness outcome is ≥ 20% reduction in mean diurnal IOP without increasing number of glaucoma medications from baseline to 12 months follow-up
  • Number of Participants With > 20% Decrease in Diurnal Intraocular Pressure
    • Time Frame: 24 months
    • The primary effectiveness outcome is ≥ 20% reduction in mean diurnal IOP without increasing number of glaucoma medications from baseline to 24 months follow-up

Secondary Measures

  • Mean Diurnal Intraocular Pressure Change
    • Time Frame: 12 months
    • Secondary Effectiveness Endpoint #1 is the mean diurnal change in IOP from Screening at 12 months.
  • Mean Diurnal Intraocular Pressure Change
    • Time Frame: 24 months
    • Secondary Effectiveness Endpoint #1 is the mean diurnal change in IOP from Screening at 24 months
  • Number of Participants With Postoperative Interventions at 12 Months
    • Time Frame: 12 months
    • The Secondary Effectiveness Endpoint #2 was having any physical or medical postoperative intervention (other than eye massage) intended to alter IOP by the Month 12 follow-up visit.
  • Participants With Postoperative Interventions at 24 Months
    • Time Frame: 24 months
    • The Secondary Effectiveness Endpoint #2 was having any physical or medical postoperative intervention (other than eye massage) intended to alter IOP by the Month 24 follow-up visit.

Participating in This Clinical Trial

Inclusion Criteria

  • POAG on maximum tolerated glaucoma meds – Medicated ≥15mmHg and ≤40mmHgExclusion Criteria:
  • Previous conjunctival incisional ophthalmic surgery - Anticipated need for additional ocular surgery during the study – Secondary glaucoma – Any condition that prevents the device implantation or trabeculectomy in the superior region of the study eye

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • InnFocus Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Paul Palmberg, M.D., Ph.D., Study Director, Bascom Palmer Eye Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.